GlassScriptPhysician profile
Tae Y Lee
NPI 1235333402
$3,610.51
in general payments reported to CMS, 2019-2025
23 companies · $1,191 in 2025
The $1,191 reported for 2025 was more than what 88% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $627 · 2020: $287 · 2021: $334 · 2022: $334 · 2023: $407 · 2024: $430 · 2025: $1,191.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,028.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,028.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $427.47 | 2021-2025 | Lybalvi, Aristada |
| Corium, LLC | $420.51 | 2022-2025 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $420.48 | 2019-2025 | Rexulti, Abilify Asimtufii |
| Ironshore Pharmaceuticals INC. | $310.14 | 2019-2024 | Jornay Pm |
| Janssen Pharmaceuticals, INC | $302.28 | 2019-2025 | Invega Sustenna, Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $289.93 | 2021-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $222.97 | 2024-2025 | Uzedy |
| Axsome Therapeutics, INC. | $182.93 | 2023-2025 | Auvelity, Sunosi |
| Adlon Therapeutics L.P. | $169.67 | 2019-2021 | |
| Neos Therapeutics, LP | $155.53 | 2019-2024 | Adzenys Xr-Odt |
| Noven Therapeutics, LLC | $146.31 | 2022-2025 | Xelstrym, Secuado |
| Tris Pharma INC | $128.31 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $84.47 | 2019-2022 | |
| Bausch Health US, LLC | $77.58 | 2019-2021 | |
| Vertical Pharmaceuticals, LLC | $53.41 | 2019-2025 | Relexxii |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $52.14 | 2023-2024 | Qelbree, Qelbree |
| Vanda Pharmaceuticals INC. | $48.79 | 2025 | Fanapt |
| Shire North American Group INC | $34.91 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $24.32 | 2019 | |
| Arbor Pharmaceuticals, INC. | $16.26 | 2019 | |
| Avanir Pharmaceuticals, INC. | $15.93 | 2019 | |
| Lundbeck LLC | $15.02 | 2023 | Rexulti |
| Merck Sharp & Dohme LLC | $11.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tae Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.